UNSPSC 51291506: Deximafen

This classification denotes an antidepressant agent with the molecular formula C11H13N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1V5135S169, chemically known as 1h-imidazo(1,2-a)imidazole, 2,3,5,6-tetrahydro-3-phenyl-, ( )- but generally known as deximafen, which bears US NIH Compound Identifier 163316. European Medicines Agency schedules Deximafen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07031MIG.

UNSPSC 51291506 Deximafen, a Commodity code, does not align with the state and local opportunities recently posted under this classification. The three most recent solicitations involve naloxone distribution, direct-to-manufacturer pharmacy programs, and generic multi-source pharmaceuticals and OTC products—none of which concerns deximafen specifically or map cleanly to the code's nominal scope. The code shows little relevant recent activity, and the mismatch between the code name and the actual procurements solicited suggests either a data classification error or minimal real-world buying activity under this designation at the state and local level.

State and local procurement bodies issuing pharmaceuticals and health products—including Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) spanning multiple states—demonstrate active buying in naloxone, OTC products, and pharmacy benefit programs. Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023) sought 1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries to Sanford, Florida. MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026) required manufacturers to supply through three authorized wholesalers with awards effective July 1, 2026, across multiple states including Oregon. Texas HHS issued an RFI in April 2026 to gather market intelligence on direct-to-manufacturer prescription fulfillment programs. Geographic activity centers on Florida, Texas, and Minnesota with multistate cooperative reach, but deximafen does not appear as a procurement focus in any of these notices.